• Gongzhen Chen, Leiming Mao, Huyan Xia, Lei Zhu, Jiamin Huang, Yingmin Lu, Xin Liu, and Ting Tang.
• First Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guizhou, China.
• Medicine (Baltimore). 2024 Jan 26; 103 (4): e36860e36860.

AbstractYi Dian Hong, belonging to the Asteraceae family, finds widespread use in traditional Chinese medicine for its effectiveness in clearing heat, detoxifying, promoting blood circulation, reducing swelling, and cooling the blood. Modern medical research has revealed that Yi Dian Hong and its proprietary Chinese medicines possess biological functions such as inhibiting tumor-specific angiogenesis and regulating immune-related molecules. However, studies have identified that the primary component of Yi Dian Hong contains pyrrolizidine alkaloids (PAs), a toxic substance with potential risks to the liver, lungs, genes, and a propensity for carcinogenicity. Many countries impose strict controls on the content of PAs in herbal medicines and products. Unfortunately, China currently lacks relevant content standards, thereby introducing greater clinical application risks. To ensure the safety of clinical use of Yi Dian Hong, this review will analyze the risk associated with Yi Dian Hong and its proprietary Chinese medicines in clinical applications based on the PAs content in these medicines and provide recommendations.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

22 keywords...

hide…